01—Abstract
Summary
Summary of the 10-K filed March 26, 1997. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals' 1996 10-K (filed March 26, 1997) describes a research-stage biotechnology company with no commercial product revenue, an accumulated deficit of $157.0 milliona at year-end 1996, and a net loss of $32.4 million ($1.33 per share) for the year.
Total 1996 revenue was $24.1 millionb, down from $27.4 million in 1995, driven mainly by lower contract research payments from Amgen and Amgen-Regeneron Partners and Sumitomo Pharmaceuticals. Cash, cash equivalents, and marketable securities rose to $97.0 million, supported by equity raises from Amgen ($48.0 million), Medtronic ($10.0 million), and Procter & Gamble ($10.0 million), and the company says these resources should fund operations into 1999. The dominant issue for investors is the January 1997 failure of the Phase III subcutaneous BDNF trial in ALS, the company's lead program.
The stock fell more than 50%c on the announcement. Independent panels later suggested possible benefit in a subset of ALS patients and a gastrointestinal effect, and the company is reviewing whether further BDNF studies are warranted under its Amgen and Sumitomo agreements. The company's pipeline has broadened into angiopoietins, MuSK/agrin for muscle atrophy, Noggin for bone disorders, and IL-6 and other cytokine ligand traps, but these are early-stage and carry no near-term revenue visibility.
Regeneron's financial position is adequate for the near term but dependent on partner funding and future financing. Its Amgen-Regeneron Partners obligations (expected $3.0 to $5.0 milliond in 1997 and significant thereafter) and capital lease and Rensselaer facility debt add to its commitments. The filing emphasizes that the outcome of the BDNF review, partner decisions, and the outcome of the CNTF patent interference proceedings remain uncertain.
02—Key points
Key Highlights
- Phase III BDNF trial in ALS failed its primary endpoints (announced January 1997); the stock declined more than 50% on the news, and further BDNF development is under review.
- 1996 net loss of $32.4 million ($1.33 per share), compared with $23.5 million ($1.19 per share) in 1995; total revenue fell to $24.1 million from $27.4 million.
- Cash, cash equivalents, and marketable securities of $97.0 million at December 31, 1996, which management says will fund operations into 1999.
- Accumulated deficit of $157.0 million; the company has never had commercial product revenue and expects losses to continue for at least several years.
- Strategic partnerships raised capital in 1996: Amgen bought 3 million shares for $48.0 million, Medtronic bought shares for $10.0 million (AXOKINE for Huntington's), and Procter & Gamble invested $10.0 million (800,000 shares issued in March 1997 at $12.50).
- Pipeline diversified beyond neurology into angiogenesis (Angiopoietins), muscle atrophy (MuSK/agrin), bone disorders (Noggin), and cytokine antagonists (IL-6 ligand traps), all of which remain early-stage.
- Ongoing funding obligations to Amgen-Regeneron Partners ($42.6 million contributed through 1996; $3.0 to $5.0 million expected in 1997) and a CNTF patent interference proceeding with Synergen (now Amgen) leave the outcome unresolved.
03—Questions
Frequently Asked Questions
Why did Regeneron's stock fall more than 50% in January 1997?
The Phase III trial of subcutaneously delivered BDNF in ALS (1,135 patients) did not demonstrate clinical efficacy on its primary endpoints, and Amgen and Regeneron announced that no further subcutaneous development for ALS was planned. The trial did confirm BDNF's safety and tolerability. Post-trial review suggested a benefit in a subset of ALS patients and a possible gastrointestinal effect, but these findings are exploratory.
How long will Regeneron's cash last?
The company believes its existing capital resources, including $97.0 million in cash, equivalents, and marketable securities at year-end 1996, will meet operating needs into 1999. It warns that spending could accelerate if development programs succeed or research expands, and it may need additional partner funding or financing.
Does Regeneron have any products generating revenue?
No. Regeneron has no commercial product sales. Its 1996 revenue came from contract research and development payments from collaborators (Amgen, Sumitomo Pharmaceuticals, Medtronic, and Procter & Gamble), contract manufacturing for Merck, and investment income. The company does not expect product revenue for at least several years, and it may never achieve one.
What are Regeneron's most significant ongoing financial commitments?
Regeneron must make capital contributions to the 50/50 Amgen-Regeneron Partners, which it expects to total $3.0 to $5.0 million in 1997, with significant amounts beyond that. It also has capital lease obligations of about $6.9 million, a $1.8 million New York State Urban Development note, and operating leases for its Tarrytown facility, which expires June 1998.
What could drive future upside or downside for Regeneron shares?
Upside depends on whether BDNF can be advanced for ALS or gastrointestinal conditions, progress in the NT-3 diabetic neuropathy trial, and results from early programs in angiopoietins, muscle, bone, and cytokines. Downside includes further BDNF setbacks, competitive ALS drugs such as Rilutek and IGF-1, partner withdrawal or termination, and adverse outcomes in the CNTF patent interference proceedings.
04—Continue